 |
|
|
| |
IDWeek
October 2 -6
2019 Washington, DC
|
| |
| |
- Population Pharmacokinetic (PPK) Modeling and Simulation of Long-Acting (LA) Cabotegravir (CAB) to Inform Strategies Following Dosing Interruptions in HIV-1 Infected Subjects - (12/02/19)
- HCV Testing and Diagnosis and their relationship to STI Screening and New Infections in a HIV+ MSM Outpatient Cohort - Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - (10/28/19)
- Results of the First Prophylactic
Hepatitis C Virus Vaccine Efficacy Trial - (10/28/19)
- Diabetes/Weight Gain; NASH, Ethnicity in HIV+
at IDWeek 2019 Oct 2-6 Wash DC - (10/24/19)
-
Experiences and Emotional Challenges of Antiretroviral Treatment -
Findings from the Positive Perspectives Study - (10/24/19)
-
"I feel empowered": Women's perspectives on and experiences with long-acting injectable anti-retroviral therapy in the United States and Spain - (10/24/19)
- Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment Among People Living With HIV - (10/24/19)
-
PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA - (10/24/19)
-
Grindr™ Use Correlates with HIV Risk & PrEP Use
in Men who Have Sex with Men, San Diego - (10/21/19)
- Clinical outcomes of patients treated with Dolutegravir functional monotherapy or Dolutegravir plus an active non-cytosine nucleoside analog: a retrospective observational cohort study of treatment-experienced patients - (10/21/19)
-
Pooled Resistance Analyses of Darunavir (DRV) Once-daily (QD) Regimens and Formulations Across 10 Clinical Studies of Treatment-naïve (TN) and Treatment-experienced (TE) Patients With Human Immunodeficiency Virus (HIV)-1 Infection - (10/21/19)
- Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment - (10/21/19)
-
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance associated mutations through 48 weeks of treatment - (10/21/19)
- Epigenetic Age Acceleration and Non-AIDS Defining Cancers Among HIV Infected Adults - (10/21/19)
-
The Utility of Olfactory Function in Distinguishing Early Stage Alzheimer's Disease from HIV-associated Neurocognitive Disorder: A Pilot Study........"supports that these PLWH may be on an AD-like cognitive trajectory" - (10/21/19)
- FRAILTY PHENOTYPE IN OLDER VIROLOGICALLY SUPPRESSED PLWH IS STRONGLY CORRELATED WITH SPECIFIC COMORBIDITIES AND TOBACCO USE
- (10/17/19)
-
Real-World Use of Ibalizumab in Physician Office infusion Centers (POICs)
- (10/17/19)
-
Do People With HIV Have to Exercise
Harder to Get Same Muscle Benefit?
- Mark Mascolini (10/17/19)
- Implementation of an HIV and Aging Clinical
Program / A Geriatrician's Approach To Aging With HIV
- (10/16/19)
-
Iceland Making Progress Toward
Eliminating HCV--But Challenges Remain - Mark Mascolini (10/16/19)
- Attaining SVR Drives Lower Liver Mortality With Treatment of HCV - Mark Mascolini (10/16/19)
- BMI Jumps Slightly With Major Maintenance Regimens, Not Just Integrase Drugs - Mark Mascolini (10/16/19)
- Hepatic Steatosis in People Living with HIV
- Effect of Sex and Race/Ethnicity - (10/16/19)
- T Cell Subsets Associated with Diabetes in Veterans With and Without HIV - (10/16/19)
- Online US/Canada Survey Finds
Preference for Long-Acting Injectable ART - Mark Mascolini (10/16/19)
- Gilead Presents New Data From the Company's HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019 - (10/16/19)
- The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/16/19)
-
Household Income and its Relationship with Patient-reported Outcomes among Older People Living with HIV - (10/15/19)
-
Characteristics Associated with Pre-Frailty
in Older People Living with HIV (47% Pre-Frailty) - (10/15/19)
-
Poor Mental Health & Quality of Life in Virally Suppressed HIV+ - (10/15/19)
-
Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/15/19)
-
Long-Term Efficacy, Safety and Durability of CAB and RPV
as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/15/19)
-
Antiretroviral Therapy Anchor-based Trends in Body Mass Index
following Treatment Initiation among Military Personnel with HIV - (10/11/19)
-
Weight Change Associated with Switching to Integrase Strand Transfer Inhibitor-based Antiretroviral Regimens in HIV-positive Subjects - (10/11/19)
- Real world utilization of ibalizumab (IBA) without
an optimized background regimen (OBT) - (10/11/19)
- IBALIZUMAB EFFICACY AND SAFETY THROUGH 48 WEEKS OF TREATMENT: RESULTS OF AN EXPANDED ACCESS PROTOCOL (TMB-311) - (10/11/19)
- Drug Injectors Accept and Use Naloxone Offered at HCV Visits - Mark Mascolini (10/11/19)
- BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Infection Switching from TDF to TAF Containing ART - (10/11/19)
-
PrEP Linked to Lower HIV Incidence in US, Independent of TasP - Mark Mascolini (10/11/19)
-
Long-Term Efficacy, Safety and Durability of CAB
and RPV as Two-Drug Oral Maintenance Therapy - LATTE Week 312 Results - (10/8/19)
-
Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women's Interagency HIV Study (WIHS) - (10/8/19)
- A Geriatrician's Approach to People Aging with HIV - Co-Morbidities and Aging - (10/8/19)
- The prevalence and burden of non-aids comorbidities in women
with or at-risk for hiv infection in the united states - (10/8/19)
- Risk of type-2 diabetes mellitus after initiating integrase and protease inhibitors in individuals living with HIV in the United States - (10/8/19)
- Changes in BMI associated with antiretroviral regimens in treatment-experienced, virologically suppressed individuals living with HIV - (10/8/19)
-
Renal Outcomes for Participants Taking F/TAF
versus F/TDF for HIV PrEP in the DISCOVER Trial
- (10/8/19)
- Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically-Suppressed Adults Living With HIV and End Stage Renal Disease on Chronic Hemodialysis - (10/8/19)
-
Oral Cabotegravir and Rilpivirine Durable for 5.5 Years in LATTE Trial
- Mark Mascolini (10/8/19)
- PrEP Significantly Reduces the Rate of New HIV Diagnoses in US Metropolitan Statistical Areas independent of Treatment as Prevention (2012-2017) - (10/8/19)
- A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV Infected Patients - (10/8/19)
- Initial DTG+3TC Noninferior to DTG+TDF/FTC; Worse Response With Low CD4s - Mark Mascolini (10/8/19)
- Pregnancy outcomes following raltegravir exposure - Mark Mascolini (10/8/19)
- Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies - (10/8/19)
- Experiences and Emotional Challenges of Antiretroviral Treatment -
Findings from the Positive Perspectives Study - (10/8/19)
- Fostemsavir Interaction Study Flags Strong CYP3A
Inducers, Statins, Oral Contraceptives - Mark Mascolini (10/8/19)
- Older and Transgender People Less Likely to Get Integrase Drugs in Big DC Cohort - Mark Mascolini (10/8/19)
- HIV Care Continuum Outcomes among newly diagnosed PLWH in Washington, DC - (10/7/19)
- ART Adherence Falls Over 4 Years in 15,000 Insured People in US - Mark Mascolini (10/7/19)
- Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
- Durable Efficacy of Two-Drug Regimen of DTG + 3TC in Antiretroviral Treatment-Naive Adults With HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies - (10/7/19)
-
HCV-Related Mortality in US Fell 4% Yearly After Arrival of DAAs - Mark Mascolini (10/7/19)
- Weight Rises--But Lipids and HbA1c Don't--After Switch to Integrase Drugs - Mark Mascolini (10/7/19)
-
High PrEP Uptake, Good Follow-up, With Mobile Screening in Florida - Mark Mascolini (10/7/19)
-
Mental Health, Quality of Life, and Accessibility to Care Among Virally-Suppressed People Living With HIV in the United States - (10/7/19)
- High Rates of Virologic Suppression Achieved in HIV-1-infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial - (10/7/19)
-
The Effect of Initiating INSTI-based vs. NNRTI-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care - (10/7/19)
- Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results From a Pooled Analysis of 7 Clinical Trials - (10/7/19)
-
Bone Safety Outcomes With F/TAF vs F/TDF for PrEP in the DISCOVER Trial - (10/7/19)
-
Switching From TDF to TAF Tied to Higher BMI and Cardio Risk - Mark Mascolini (10/7/19)
- Online US/Canada Survey Finds Preference
for Long-Acting Injectable ART - Mark Mascolini (10/4/19)
- Community Clinics Control HIV as Well
as Hospital Clinic in Chicago MSM - Mark Mascolini (10/4/19)
- Possible Higher Diabetes Risk With INSTIs or PIs Than NNRTIs - Mark Mascolini (10/4/19)
-
AIDS Mortality Does Not Differ by Race
in US Group--But "Room for Improvement" - Mark Mascolini (10/4/19)
- MSM Grindr Users Take More Sex Risks But Seem More Open to PrEP - Mark Mascolini (10/4/19)
- High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
-
Over Half of Mostly Black US HIV Group
Has NAFLD--and Many Have NASH - Mark Mascolini (10/4/19)
- HIV Suppression and Safety With Ibalizumab
at 48 Weeks in Expanded Access - Mark Mascolini (10/4/19)
-
Women With HIV and Prolonged Amenorrhea
Run Higher Risk of Hip Bone Loss - Mark Mascolini (10/4/19)
- Lower Statin Prescription Rate for
Blacks, Hispanics With HIV in US Military - Mark Mascolini (10/4/19)
- Syphilis, Gonorrhea Tied to HCV in MSM and Trans Women With HIV - Mark Mascolini (10/4/19)
-
Higher Steatosis Risk in HIV+ Hispanics,
But No Link to Integrase Inhibitors - Mark Mascolini (10/4/19)
-
Lower Screening Rates for Breast and
Cervical Cancer in Women With HIV - Mark Mascolini (10/4/19)
- High HIV Control Rate With Rapid D/C/F/TAF in Newly Diagnosed - Mark Mascolini (10/4/19)
- IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV - (10/03/19)
|
|
| |
|
|
|
|
|
|
